SCHEMBL888030

SCHEMBL888030

CC(N)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
CYP1A2 P05177 2/20 0.50
HSD17B10 Q99714 1/20 0.50
TSHR P16473 4/20 0.47
TDP1 Q9NUW8 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
GPR35 Q9HC97 1/20 0.42
PLAU P00749 1/20 0.42
PTPRC P08575 1/20 0.42
S100A4 P26447 1/20 0.42
PDE7A Q13946 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30487743 1.00 ALDH1A1 (0.53) ALDH1A1CYP1A2HSD17B10TSHRTDP1
SCHEMBL30100732 1.00 ALDH1A1 (0.53) ALDH1A1CYP1A2HSD17B10TSHRTDP1
SCHEMBL31134288 1.00 ALDH1A1 (0.53) ALDH1A1CYP1A2HSD17B10TSHRTDP1
SCHEMBL16011382 1.00 ALDH1A1 (0.53) ALDH1A1CYP1A2HSD17B10TSHRTDP1
Hydrochloric Acid SCHEMBL20521483 0.98 ALDH1A1 (0.51) ALDH1A1CYP1A2HSD17B10TSHRTDP1
Hydrochloric Acid SCHEMBL2890849 0.98 ALDH1A1 (0.51) ALDH1A1CYP1A2HSD17B10TSHRTDP1
SCHEMBL7775829 0.83 CYP1A2 (0.58) ALDH1A1CYP1A2HSD17B10TSHRTDP1
SCHEMBL16284318 0.83 ALDH1A1 (0.56) ALDH1A1CYP1A2HSD17B10TSHRTDP1
SCHEMBL18912100 0.83 CYP1A2 (0.53) ALDH1A1CYP1A2HSD17B10TSHRTDP1
SCHEMBL16687493 0.83 ALDH1A1 (0.56) ALDH1A1CYP1A2HSD17B10TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118806889-A Method for improving adsorption of polysaccharide-protein conjugates and multivalent vaccine formulations obtained therefrom 印度血清研究所私人有限公司 2024-10-22 CN claimed
EP-4025246-A2 IMMUNOGENIC COMPOSITIONS AGAINST ENTERIC DISEASES AND METHODS FOR ITS PREPARATION THEREOF Serum Institute Of India Private Limited (IN) 2022-07-13 EP claimed
CN-114728053-A Immunogenic compositions against intestinal disease and process for preparing same 印度血清研究所私人有限公司 2022-07-08 CN claimed
WO-2021044436-A2 IMMUNOGENIC COMPOSITIONS AGAINST ENTERIC DISEASES AND METHODS FOR ITS PREPARATION THEREOF SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) 2021-03-11 WO claimed
EP-2254890-A1 PROCESS FOR THE DIASTEREOISOMERIC RESOLUTION OF 5-METHYLTETRAHYDROFOLIC ACID Gnosis S.p.A. (IT) 2010-12-01 EP claimed
WO-2009103333-A1 PROCESS FOR THE DIASTEREOISOMERIC RESOLUTION OF 5-METHYLTETRAHYDROFOLIC ACID GNOSIS S.P.A. (IT) 2009-08-27 WO claimed
EP-1476197-A2 SYNTHESIS OF LIPOPOLYSACCHARIDE-PROTEIN CONJUGATE VACCINES VIA THE LIPID A REGION FOLLOWING REMOVAL OF THE GLYCOSIDIC PHOSPHATE RESIDUE NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2004-11-17 EP claimed
WO-2003070282-A2 SYNTHESIS OF LIPOPOLYSACCHARIDE-PROTEIN CONJUGATE VACCINES VIA THE LIPID A REGION FOLLOWING REMOVAL OF THE GLYCOSIDIC PHOSPHATE RESIDUE NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2003-08-28 WO claimed
JP-7109250-A None JP disclosed
US-12509431-B2 1,4-dihydroquinazolinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-12-30 US disclosed
US-20250361213-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2025-11-27 US disclosed
EP-4594307-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2025-08-06 EP disclosed
US-20250154111-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-05-15 US disclosed
CN-119822969-A Method for continuously preparing 4-nitrophenethylamine and salt thereof 浙江华海药业股份有限公司 2025-04-15 CN disclosed
EP-0107149-B1 NOVEL NAPHTHALENE DERIVATIVES AND METHOD FOR PREPARATION THEREOF Tanabe Seiyaku Co., Ltd. (JP) 1985-10-16 EP disclosed
US-4508882-A ULTRAVIOLET ADSORBERS ASAHI GLASS COMPANY LTD. (JP) 1985-04-02 US disclosed
EP-0107149-A1 Novel naphthalene derivatives and method for preparation thereof Tanabe Seiyaku Co., Ltd. (JP) 1984-05-02 EP disclosed
US-4380643-A Benzotriazole compound and homopolymer or copolymers thereof ASAHI GLASS COMPANY, LTD. (JP) 1983-04-19 US disclosed
US-4374061-A ACTIVATION, AMINATION, AND DIAZOTIZATION OF A POLYSACCHARIDE FOLLOWED BY REACTION WITH A GLOBULIN; CHROMATOGRAPHY; SEPARATION OF GLYCOPROTEINS CENTER FOR BLOOD RESEARCH, INC. (US) 1983-02-15 US disclosed
US-3995059-A CHOLESTEROL LOWERING AGENTS SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509431-B2 1,4-dihydroquinazolinone compounds and uses thereof TNNT2, TNNI3, TNNC1 ALDH1A1 716/4885CYP1A2 942/4885HSD17B10 16/4885
US-20250154111-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, SDHA ALDH1A1 780/4885CYP1A2 1264/4885HSD17B10 130/4885
US-20250361213-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, SDHA ALDH1A1 780/4885CYP1A2 1264/4885HSD17B10 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.